Chris Slavinsky
Corporate Officer/Principal bij TAKEDA PHARMACEUTICAL COMPANY LIMITED
Profiel
Chris Slavinsky is currently the VP-External Innovation & Head-Gastroenterology at Takeda Pharmaceutical Co., Ltd.
Prior to this, he held positions as the Director at Phathom Pharmaceuticals, Inc., Director at ARTham Therapeutics, Inc., General Counsel & Head-Business Development at Prometheus Biosciences, Inc., and General Counsel at Pharmacosmos Therapeutics Inc. He also served as the Chief Legal & Business Officer at Coherus BioSciences, Inc. from 2022 to 2023.
Mr. Slavinsky has a graduate degree from Thomas Jefferson University, an undergraduate degree from Stony Brook University, and a graduate degree from Washington University School of Law.
Actieve functies van Chris Slavinsky
| Bedrijven | Functie | Begin |
|---|---|---|
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Corporate Officer/Principal | - |
Eerdere bekende functies van Chris Slavinsky
| Bedrijven | Functie | Einde |
|---|---|---|
| COHERUS BIOSCIENCES, INC. | Algemeen Adviseur | 01-10-2023 |
| PHATHOM PHARMACEUTICALS, INC. | Directeur/Bestuurslid | 30-11-2019 |
ARTham Therapeutics, Inc.
 ARTham Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Kaken Pharmaceutical Co., Ltd., ARTham Therapeutics, Inc. is a pharmaceutical company based in Yokohama, Japan. The Japanese company's mission is to deliver "medicines that matter" to improve patient health and contribute to enhanced quality of life through the development of innovative disease-modifying medicines. The company was founded by Sham Nikam, Naoto Uemura, and has been led by CEO Hiroshi Nagabukuro since 2018. ARTham Therapeutics was acquired by Kaken Pharmaceutical Co., Ltd. on December 13, 2021 for $111.95 million. | Directeur/Bestuurslid | - |
| Pharmacosmos Therapeutics Inc. | Algemeen Adviseur | - |
| PROMETHEUS BIOSCIENCES, INC. | Algemeen Adviseur | - |
Opleiding van Chris Slavinsky
| Thomas Jefferson University | Graduate Degree |
| Stony Brook University | Undergraduate Degree |
| Washington University School of Law | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Health Technology |
| COHERUS BIOSCIENCES, INC. | Health Technology |
| PHATHOM PHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Prometheus Biosciences, Inc.
 Prometheus Biosciences, Inc. BiotechnologyHealth Technology Prometheus Biosciences, Inc. engages in operation of a biopharmaceutical company. It focuses on the discovery, development, and commercialization of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases. The company was founded by Scott Glenn and Stephan Targan on October 26, 2016 and is headquartered in San Diego, CA . | Health Technology |
ARTham Therapeutics, Inc.
ARTham Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Kaken Pharmaceutical Co., Ltd., ARTham Therapeutics, Inc. is a pharmaceutical company based in Yokohama, Japan. The Japanese company's mission is to deliver "medicines that matter" to improve patient health and contribute to enhanced quality of life through the development of innovative disease-modifying medicines. The company was founded by Sham Nikam, Naoto Uemura, and has been led by CEO Hiroshi Nagabukuro since 2018. ARTham Therapeutics was acquired by Kaken Pharmaceutical Co., Ltd. on December 13, 2021 for $111.95 million. | Health Technology |
| Pharmacosmos Therapeutics Inc. |
